UK markets closed

Vivoryon Therapeutics N.V. (0R3M.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
0.4799-0.0001 (-0.01%)
At close: 05:49PM BST
Full screen
Previous close0.4800
Open0.4805
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.4700 - 0.4837
52-week range0.4700 - 19.4000
Volume60,675
Avg. volume3,012
Market cap62,672
Beta (5Y monthly)1.27
PE ratio (TTM)N/A
EPS (TTM)-0.6330
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024

    Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024 Halle (Saale) / Munich, Germany, April 16, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it will publish its financial results for the full year 2023 and pro

  • GlobeNewswire

    Vivoryon Therapeutics N.V. Announces Changes to Board Composition

    Vivoryon Therapeutics N.V. Announces Changes to Board Composition Halle (Saale) / Munich, Germany, March 15, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced changes among the Non-Executive members of its Board of Directors. Professor Morten Asser Karsdal, MSc, PhD, mMBA and Ku

  • Simply Wall St.

    Here's Why Vivoryon Therapeutics (AMS:VVY) Must Use Its Cash Wisely

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...